Astria Therapeutics, Inc. - Common Stock (ATXS)

BioCryst will acquire Astria Therapeutics for $700 million to expand its HAE portfolio with navenibart, aiming for double-digit revenue growth.

Let's delve into the US markets on Tuesday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.

As we await the opening of the US market on Tuesday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.

Astria Therapeutics reports Q2 2025 results with a narrower-than-expected loss, extended cash runway, and progress in clinical trials for navenibart and STAR-0310.

Shares of Rumble Inc.

ATXS stock results show that Astria Therapeutics missed analyst estimates for earnings per share the second quarter of 2024.

ATXS stock results show that Astria Therapeutics missed analyst estimates for earnings per share the first quarter of 2024.

Shares of Lifecore Biomedical, Inc. (NASDAQ: LFCR) fell sharply during Wednesday’s session after the company announced it concluded its strategic evaluation process, announced management succession and board changes. Lifecore Biomedical shares dipped 31.7% to $4.91 on Wednesday.

ATXS stock results show that Astria Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023.

Although U.S. stocks closed mixed on Friday, there were a few notable insider trades.

Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is expected to report earnings for its third quarter. • Dixie Gr (NASDAQ:DXYN) is estimated to report earnings for its third quarter.